Participants in the study will receive injections of either the vaccine or a placebo over a period of up to 12 months. The study will monitor the participants’ symptoms and any medication they use during the grass and olive tree pollen season, which typically occurs in April, May, and June. The study will also look at the number of days participants are free from symptoms and medication, any worsening of asthma symptoms, and overall quality of life related to rhinitis. Additionally, the study will assess the safety of the vaccine by tracking any side effects or reactions at the injection site.

The trial aims to provide valuable information on whether the vaccine can help reduce symptoms and improve the quality of life for people with allergies to grasses and olive trees. By comparing the vaccine to a placebo, researchers hope to determine its effectiveness in managing these allergic conditions. The study will also gather data on various health measures, including levels of specific antibodies in the blood, to better understand the vaccine’s impact on the immune system.

In the study, participants receive repeated injections over about one year. During this time, symptoms, asthma problems if present, and any unwanted effects are tracked in a diary and during study visits. The study looks at whether the treatment can help control allergy symptoms and improve day-to-day comfort in people allergic to dust mites and Blomia tropicalis.

The study is designed for people with allergy caused by Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Blomia tropicalis, which are types of house dust mites and a related allergen source. The purpose of the study is to evaluate the efficacy and safety of this allergy treatment in rhinitis/rhinoconjunctivitis with or without controlled mild to moderate asthma.

People in the study are assigned by chance to receive either the active injection or placebo, and neither the participants nor the study team know which one is given. The treatment is given under the skin over a period of time. During the study, allergy and asthma symptoms, use of allergy or asthma medicines, and possible side effects are followed over about one year of treatment.

The study includes people with moderate to severe allergy symptoms, with or without controlled mild asthma. It is designed to learn whether this form of immunotherapy, a treatment that helps the body become less sensitive to an allergen, can improve day-to-day symptoms and safety in people allergic to these dust-related allergens.

The purpose of this study is to determine how well each dose of the treatment works and how safe it is by measuring symptoms and the need for rescue medication. The study will also examine which dose provides the best balance between effectiveness and safety. During the study, participants will use an electronic diary to record their symptoms and any medication they take. The treatment is given as a spray under the tongue and will be administered over a period of time. The study will measure various aspects of the participants’ condition, including how severe their symptoms are, how often they need to use rescue medication, and how their quality of life is affected by their allergies.

Before and after the treatment period, participants will undergo a nasal provocation test, which involves exposing the inside of the nose to increasing amounts of house dust mite extract to see how the body reacts. This test helps determine whether the treatment has made the immune system less sensitive to the allergen. The study will track the number of days when participants feel well, when symptoms are severe, and when they are completely free of symptoms. Quality of life will be measured using questionnaires, and participants will rate their overall discomfort using a scale. Safety will be monitored throughout the study by recording any unwanted reactions to the treatment.

The study will compare different strengths of the allergen mixture (1000, 3000, and 6000 TBU/ml) against a placebo. The medication or placebo will be given as a sublingual spray, which means it is sprayed under the tongue. Participants will receive daily doses for 4 months. To measure how well the treatment works, doctors will perform a nasal provocation test, which involves putting a small amount of allergen in the nose and measuring breathing changes.

During the study, participants will have various tests to check their allergy responses, including skin prick tests and blood tests to measure antibody levels. Doctors will also monitor any side effects and keep track of how often participants need to use other allergy medications. The treatment is designed for people who have allergic reactions to dust mites, which can cause symptoms like sneezing, runny nose, and itchy eyes.

The purpose of the study is to evaluate how effective and safe this vaccine is for people aged 12 to 65 who have moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate controlled asthma. Participants will receive either the vaccine or a placebo, which looks like the vaccine but does not contain the active ingredients. The study will last for about a year, during which participants will receive regular injections and will be asked to keep track of their symptoms and any medications they use in a diary.

Throughout the study, participants’ symptoms and medication use will be closely monitored to assess the vaccine’s effectiveness. The study will also look at various health measures, including the quality of life related to asthma and rhinitis, and any side effects that may occur. The goal is to determine if the vaccine can help reduce the symptoms of allergic rhinitis and rhinoconjunctivitis and improve the overall quality of life for those affected by these conditions.

The purpose of the study is to assess how effective and safe this vaccine is compared to a placebo, which looks like the real treatment but does not contain any active ingredients. Participants in the study will receive either the vaccine or the placebo over a period of time. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications. It will also look at the safety of the treatment by checking for any side effects.

Participants will be asked to keep track of their symptoms and any medications they take in a diary. The study will include people aged 12 to 65 who have moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The trial aims to provide valuable information on whether this new vaccine can offer relief to those affected by house dust mite allergies.

The treatment involves receiving injections of Alutard SQ dog, which contains small amounts of dog allergens. These allergens are substances from dogs that cause allergic reactions in some people. During the study, participants may also use other allergy medications to help manage their symptoms. The study will last for approximately one year.

The researchers will measure how well the treatment works by checking changes in nasal symptoms and using a rating scale to assess allergy symptoms when exposed to dog dander. They will also monitor breathing ability and check for any changes in eye symptoms. Throughout the study, doctors will keep track of any side effects that may occur during the treatment.

The purpose of the study is to evaluate how effective and safe the Sublingual MM09 treatment is compared to a placebo, which looks like the treatment but does not contain the active ingredients. Participants in the study will use the spray daily for 12 months. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications. Participants will be asked to keep a diary of their symptoms and any medications they take during the study.

This trial is designed to be a double-blind study, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will include people aged 12 to 65 who have been diagnosed with moderate to severe rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, due to house dust mite allergies. The goal is to see if the Sublingual MM09 can help improve their quality of life by reducing allergy symptoms and the need for other treatments.

The purpose of the study is to assess how well Lebrikizumab can reduce the total nasal symptoms in adults with perennial allergic rhinitis over a period of 16 weeks. Participants will be randomly assigned to receive either the medication or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study, which helps ensure the results are unbiased.

Throughout the study, participants will attend regular visits to monitor their symptoms and overall health. The main focus will be on changes in the severity of nasal symptoms from the start of the study to the end of the 16-week period. The study aims to provide valuable information on the potential benefits of Lebrikizumab for individuals suffering from perennial allergic rhinitis.

The purpose of the study is to evaluate how well the vaccine works in reducing symptoms and the need for medication during the pollen seasons of grasses and cupressaceae, which are types of plants that can cause allergies. Participants will receive the vaccine or placebo over a period of 12 months. Throughout the study, participants will be monitored for any changes in their symptoms, the number of days they are symptom-free, and any asthma flare-ups. The study will also assess the overall safety of the vaccine by tracking any side effects or reactions at the injection site.

Participants will be asked to record their symptoms and medication use using a smartphone app. The study will also measure certain immune system markers, such as total IgE and specific IgG4, which are types of antibodies related to allergies. Additionally, the study will evaluate the participants’ quality of life and asthma control using questionnaires. The trial aims to provide valuable information on whether this new vaccine can help people with grass and cupressaceae allergies manage their symptoms more effectively.

The purpose of the study is to evaluate how well this vaccine works in reducing allergy symptoms and the need for medication in people who are allergic to these dust mites. Participants in the study will receive either the Clustoid MM09 vaccine or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will last for up to 12 months, during which participants will receive regular injections and will be monitored for any changes in their allergy symptoms and overall health.

Throughout the study, participants will be asked to keep track of their symptoms and any medications they take using a smartphone app. The study aims to provide valuable information on the potential benefits of the Clustoid MM09 vaccine for people with dust mite allergies, potentially leading to improved treatment options for those affected by these common allergens.

The purpose of the study is to assess how well the vaccine works in reducing allergy symptoms in adolescents and adults who suffer from these conditions. Participants will receive the vaccine or placebo through injections over a period of time. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual vaccine or the placebo, to ensure unbiased results.

Throughout the study, participants will be monitored to see how their symptoms change during the peak birch pollen season. The main goal is to determine if the vaccine can effectively reduce the symptoms and the need for other allergy medications. This research could lead to a new way to manage birch pollen allergies and improve the quality of life for those affected by these seasonal conditions.

Participants in the study will receive either the ILIT treatment with vitamin D, ILIT without vitamin D, or a placebo. The purpose of the study is to determine if the combination of ILIT and vitamin D leads to a significant improvement in symptoms during the grass pollen season compared to ILIT alone. The study will monitor participants over a period of time to assess changes in their symptoms and quality of life related to their allergy.

The study will involve several visits where participants will receive their assigned treatment and undergo assessments to track their progress. These assessments will include questionnaires about their symptoms and quality of life, as well as tests to measure immune responses. The goal is to find out if the combination of ILIT and vitamin D can provide better relief from hay fever symptoms compared to other treatments.

The purpose of the study is to see how effective this treatment is in reducing the symptoms of allergic rhinitis and rhinoconjunctivitis over a period of one year. Participants will receive either the PURETHAL treatment or a placebo. The study will involve regular visits to the clinic for injections and assessments. Participants will be asked to keep a daily diary of their symptoms and any changes they notice. The study will also monitor the safety of the treatment and any side effects that may occur.

In addition to the main treatment, the study will use various tests to assess the participants’ allergic reactions. These include skin-prick tests with substances like dog epithelia, cat epithelia, and mugwort pollen extract, as well as nasal sprays and eye drops containing substances like loratadine and azelastine. These tests help to understand how the body reacts to different allergens and to measure the effectiveness of the treatment. The study aims to provide valuable information on managing allergic conditions caused by house dust mites.

Participants in the study will receive either the SULGEN® Spray Betula verrucosa or a placebo. The study will compare the effects of the spray with the placebo to see how well it works in reducing symptoms and improving the quality of life for those with birch pollen allergies. The trial will also monitor any side effects to ensure the treatment is safe. The study will last for a period that includes the peak birch pollen season, allowing researchers to assess the treatment’s effectiveness during the time when symptoms are usually at their worst.

Throughout the study, participants will be asked to keep a diary of their symptoms and any medication they take. This information will help researchers understand how the treatment affects daily life and symptom management. The goal is to determine if the SULGEN® Spray Betula verrucosa can provide a better balance of benefits and risks compared to not using the active treatment. The study is expected to conclude by August 2025.